title: Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma.
abstract: OBJECTIVE
  Cysteine-rich, angiogenic inducer, 61 (CYR61) is a key gene in the transforming growth factor-β signalling pathway, which is involved in the development of many tumour types. This study aimed to clarify the status and clinical significance of CYR61 expression in patients with ovarian epithelial carcinoma.
  
  
  METHODS
  Tissue from patients with ovarian epithelial carcinoma or benign ovarian tumours were investigated retrospectively for CYR61 expression at mRNA and protein levels, using reverse transcription-polymerase chain reaction and immunohistochemistry, respectively. Correlations between immunohistochemical scores and several clinicopathological parameters were investigated.
  
  
  RESULTS
  In 50 patients with ovarian epithelial carcinoma and 50 patients with benign ovarian tumours, CYR61 expression on mRNA and protein levels was significantly higher in ovarian epithelial carcinoma tissue than in benign ovarian tissue. CYR61 expression was associated with regional lymph node metastases and progression of clinical disease stage. There was no difference in CYR61 expression between patients aged <50 years and ≥ 50 years.
  
  
  CONCLUSIONS
  CYR61 expression was significantly upregulated in ovarian carcinoma tissue compared with benign ovarian tumour tissue samples. Protein CYR61 levels were associated with lymph node metastases and Union for International Cancer Control stage. Protein CYR61 may be useful in targeted diagnosis and therapy, for patients with ovarian epithelial carcinoma.
authors.affiliation: Department of Obstetrics and Gynaecology, the Second Hospital, Jilin University, Changchun, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Lin
authors.forename: Tianmin
authors.initials: T
authors.lastname: Xu
authors.forename: Geng
authors.initials: G
authors.lastname: Tian
authors.forename: Manhua
authors.initials: M
authors.lastname: Cui
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D000077216:Carcinoma, Ovarian Epithelial; D055515:Cysteine-Rich Protein 61 / Q000096:biosynthesis / Q000235:genetics*; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D010053:Ovary / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C501848:CCN1 protein, human; D055515:Cysteine-Rich Protein 61; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta
keywords: 61 (CYR61); Cysteine-rich; Ovarian cancer; angiogenic inducer; immunohistochemistry; ovarian epithelial carcinoma